Physician profile
Lily Wang
NPI 1639566102
$12,887.39
in general payments reported to CMS, 2019-2025
52 companies · $80.56 in 2025
The $80.56 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,660 · 2022: $4,213 · 2023: $3,144 · 2024: $1,790 · 2025: $80.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,440 · Education: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,440.00 |
| Education | $575.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,103.06 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $1,057.91 | 2021-2023 | Padcev, Tukysa, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $882.81 | 2021-2024 | Opdivo, Krazati, Augtyro |
| Incyte Corporation | $856.63 | 2021-2024 | Monjuvi, Pemazyre, Jakafi |
| Astrazeneca Pharmaceuticals LP | $852.83 | 2021-2024 | Enhertu, Lynparza |
| Pfizer INC. | $669.66 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $621.39 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $600.01 | 2021-2025 | |
| Daiichi Sankyo INC. | $585.10 | 2021-2024 | Enhertu |
| Janssen Biotech, INC. | $585.06 | 2021-2024 | Imbruvica, Tecvayli, Darzalex |
| Celgene Corporation | $560.13 | 2021-2024 | Reblozyl, Pomalyst |
| Eisai INC. | $557.25 | 2021-2024 | |
| Astellas Pharma US INC | $506.93 | 2021-2024 | Xospata, Vyloy, Xtandi |
| Amgen INC. | $405.47 | 2021-2023 | Lumakras |
| Puma Biotechnology, INC. | $372.10 | 2021-2024 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.